Antiprothrombin antibodies induce platelet activation: A possible explanation for anti-FXa therapy failure in patients with antiphospholipid syndrome?
Walid ChayouaPhillip L R NicolsonJoost C M MeijersCaroline KardebyLourdes Garcia-QuintanillaKatrien M J DevreeseBas de LaatStephen P WatsonPhilip G de GrootPublished in: Journal of thrombosis and haemostasis : JTH (2021)
Antiprothrombin antibodies with LAC activity are able to activate platelets via FcγRIIA. Decreased prothrombin levels resulted in less antiprothrombin antibody-mediated platelet aggregation. This may explain the lower incidence of arterial thrombosis in patients treated with warfarin than with anti-FXa therapy.